To assess whether IL-2 signaling is required for IL12R upregulation on tumor-reactive T cells in the TdLN, we primed naive cell trace violet–labeled (CTV-labeled) CD8+ T cells with plate-bound CD3 and CD28 agonist antibodies in the presence or absence of neutralizing IL-2 antibodies (Figure 2G). This evidence concerns the gene CD28 and neoplasm.